Brian Skorney
Stock Analyst at Baird
(3.84)
# 693
Out of 5,124 analysts
121
Total ratings
48.28%
Success rate
10.91%
Average return
Main Sectors:
Stocks Rated by Brian Skorney
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $80 → $88 | $78.99 | +11.41% | 6 | Dec 9, 2025 | |
| ANRO Alto Neuroscience | Maintains: Outperform | $16 → $22 | $17.80 | +23.60% | 4 | Nov 13, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Neutral | $21 → $15 | $21.52 | -30.30% | 13 | Nov 4, 2025 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Outperform | $58 → $62 | $46.55 | +33.19% | 5 | Sep 26, 2025 | |
| BHVN Biohaven | Maintains: Outperform | $57 → $52 | $11.29 | +360.58% | 4 | Aug 12, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Outperform | $180 → $186 | $141.83 | +31.14% | 5 | Jul 31, 2025 | |
| SLNO Soleno Therapeutics | Maintains: Outperform | $105 → $121 | $46.30 | +161.34% | 5 | Jul 11, 2025 | |
| DYN Dyne Therapeutics | Maintains: Outperform | $46 → $32 | $19.56 | +63.60% | 2 | Jun 18, 2025 | |
| BIIB Biogen | Maintains: Outperform | $300 → $255 | $175.99 | +44.89% | 17 | May 2, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $652 → $587 | $771.87 | -23.95% | 15 | Apr 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $95 → $100 | $122.74 | -18.53% | 3 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $13.47 | +122.72% | 1 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $5 | $0.10 | +4,900.00% | 4 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $20 | $15.77 | +26.82% | 6 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $9.76 | +156.15% | 1 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $215 | $327.31 | -34.31% | 4 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $9.93 | +181.97% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $39 | $14.41 | +170.65% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $63 | $44.82 | +40.56% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $280 → $325 | $453.36 | -28.31% | 14 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $10 | $25.42 | -60.66% | 2 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $270 | $0.66 | +40,691.66% | 1 | May 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $18 → $6 | $3.93 | +52.67% | 1 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $600 → $300 | $0.99 | +30,292.06% | 3 | May 7, 2018 |
Mirum Pharmaceuticals
Dec 9, 2025
Maintains: Outperform
Price Target: $80 → $88
Current: $78.99
Upside: +11.41%
Alto Neuroscience
Nov 13, 2025
Maintains: Outperform
Price Target: $16 → $22
Current: $17.80
Upside: +23.60%
Sarepta Therapeutics
Nov 4, 2025
Maintains: Neutral
Price Target: $21 → $15
Current: $21.52
Upside: -30.30%
Crinetics Pharmaceuticals
Sep 26, 2025
Maintains: Outperform
Price Target: $58 → $62
Current: $46.55
Upside: +33.19%
Biohaven
Aug 12, 2025
Maintains: Outperform
Price Target: $57 → $52
Current: $11.29
Upside: +360.58%
Neurocrine Biosciences
Jul 31, 2025
Maintains: Outperform
Price Target: $180 → $186
Current: $141.83
Upside: +31.14%
Soleno Therapeutics
Jul 11, 2025
Maintains: Outperform
Price Target: $105 → $121
Current: $46.30
Upside: +161.34%
Dyne Therapeutics
Jun 18, 2025
Maintains: Outperform
Price Target: $46 → $32
Current: $19.56
Upside: +63.60%
Biogen
May 2, 2025
Maintains: Outperform
Price Target: $300 → $255
Current: $175.99
Upside: +44.89%
Regeneron Pharmaceuticals
Apr 30, 2025
Maintains: Neutral
Price Target: $652 → $587
Current: $771.87
Upside: -23.95%
Feb 12, 2025
Maintains: Neutral
Price Target: $95 → $100
Current: $122.74
Upside: -18.53%
Dec 13, 2024
Initiates: Outperform
Price Target: $30
Current: $13.47
Upside: +122.72%
Nov 29, 2024
Maintains: Outperform
Price Target: $14 → $5
Current: $0.10
Upside: +4,900.00%
Nov 26, 2024
Maintains: Outperform
Price Target: $26 → $20
Current: $15.77
Upside: +26.82%
Oct 31, 2024
Initiates: Outperform
Price Target: $25
Current: $9.76
Upside: +156.15%
Sep 25, 2024
Reiterates: Underperform
Price Target: $215
Current: $327.31
Upside: -34.31%
Jun 13, 2024
Initiates: Outperform
Price Target: $28
Current: $9.93
Upside: +181.97%
Mar 6, 2024
Maintains: Outperform
Price Target: $34 → $39
Current: $14.41
Upside: +170.65%
Dec 8, 2023
Initiates: Outperform
Price Target: $63
Current: $44.82
Upside: +40.56%
May 2, 2023
Maintains: Neutral
Price Target: $280 → $325
Current: $453.36
Upside: -28.31%
Aug 3, 2021
Downgrades: Neutral
Price Target: $10
Current: $25.42
Upside: -60.66%
May 20, 2021
Initiates: Outperform
Price Target: $270
Current: $0.66
Upside: +40,691.66%
Feb 26, 2021
Downgrades: Neutral
Price Target: $18 → $6
Current: $3.93
Upside: +52.67%
May 7, 2018
Maintains: Outperform
Price Target: $600 → $300
Current: $0.99
Upside: +30,292.06%